Lexaria Bioscience Corp. has released additional results from its Phase 1b clinical study, GLP-1-H24-4, recently completed in Australia. The study evaluated four DehydraTECH™ $(DHT)$ study arms in comparison to the Rybelsus® control arm over a 12-week period. According to the company, secondary efficacy parameters assessed at week 16—such as mean fasting glucose, cholesterol, and LDL cholesterol—showed no statistically significant differences between the DHT arms and the Rybelsus® control. Lexaria stated that the complete study report exceeds 7,000 pages and that additional details are under review. The company also indicated plans for further clinical testing and research in the GLP-1 sector, with updates on development opportunities expected in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1122163) on December 30, 2025, and is solely responsible for the information contained therein.